TABLE 1.
Demographic and Clinical Characteristics for Schizophrenia Patients Randomly Assigned to MK-0777 or Placebo
| Treatment Group |
Age (years) |
Education (years) |
Marital Status |
Age at Onset of Illness (years) |
Duration of Illness (years)a |
Antipsychotic Treatment |
|---|---|---|---|---|---|---|
| Placebo | 31 | 12 | Single | 19 | 12 | Clozapine (325 mg/day) |
| MK-0777 | 46 | 12 | Married | 43 | 3 | Risperidone (4 mg/night) |
| MK-0777 | 23 | 10 | Separated | 20 | 3 | Risperidone (1 mg/night and 25 mg [intramuscular]/2 weeks) |
| Placebo | 34 | 14 | Single | 20 | 14 | Clozapine (100 mg/morning and 300 mg/night); Risperidone (2 mg/night) |
| MK-0777 | 49 | 13 | Single | 21 | 28 | Clozapine (375 mg/night) |
| MK-0777 | 46 | 12 | Single | 21 | 25 | Risperidone (3 mg/night) |
| Placebo | 38 | 13 | Divorced | 15 | 24 | Aripiprazole (30 mg/day) |
| Placebo | 48 | 10 | Single | 17 | 31 | Aripiprazole (30 mg/day); Haloperidol (6 mg/night) |
| MK-0777 | 50 | 9 | Single | 21 | 29 | Risperidone (2 mg/day); Haloperidol decanoate (25 mg/month) |
| MK-0777 | 45 | 16 | Single | 28 | 18 | Olanzapine (20 mg/night) |
| MK-0777 | 40 | 9 | Single | 17 | 24 | Olanzapine (7.5 mg/night); Fluphenazine decanoate (50 mg/2 weeks) |
| Placebo | 34 | 7 | Single | 25 | 9 | Risperidone (3 mg/night and 37.5 mg [intramuscular]/2 weeks); Ziprasidone (80 mg b.i.d.) |
| Placebo | 29 | 8 | Single | 29 | 1 | Quetiapine (800 mg/night) |
| MK-0777 | 31 | 10 | Single | 19 | 12 | Olanzapine (10 mg/night) |
| MK-0777 | 24 | 13 | Single | 18 | 6 | Risperidone (3 mg/night) |
a
Duration of illness was measured from the onset of the first psychotic symptoms to the date of consent to participate in the study.